Pennsylvania is currently home to 3313 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
NCT05964413
Recruiting
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pyoderma Gangrenosum
Register for Updates
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
NCT05535192
Recruiting
This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.
Gender:
FEMALE
Ages:
65 years and above
Trial Updated:
03/26/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Breast Cancer, Stage III Breast Cancer, Breast Cancer Female, Stage I Breast Cancer, Stage II Breast Cancer
Register for Updates
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/26/2025
Locations: Abington Neurological Associates, Abington, Pennsylvania
Conditions: Early Alzheimer's Disease
Register for Updates
Children's Bipolar Network Treatment Trial I
NCT05427123
Recruiting
This is a naturalistic treatment and follow-up study of youth with bipolar spectrum disorders (BSDs) across four US sites of The Childhood Bipolar Network (CBN). CBN sites have expertise in diagnosing, assessing, and treating BSDs in youth. The primary aims of this study are to (1) identify and reliably diagnose youth (ages 9 to 19 yrs) with full bipolar disorder (BD) and BSDs, and (2) examine predictors (e.g., mood instability, inflammatory marker C-reactive protein) of clinical outcome over a... Read More
Gender:
ALL
Ages:
Between 9 years and 19 years
Trial Updated:
03/26/2025
Locations: University of Pittsburgh Child and Adolescent Bipolar Spectrum Services Clinic (CABS), Pittsburgh, Pennsylvania
Conditions: Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Other Specified Bipolar and Related Disorder, Mood Instability, Child Mental Disorder, Adolescent - Emotional Problem
Register for Updates
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
NCT04963153
Recruiting
This phase Ib trial evaluates the best dose, potential benefits, and/or side effects of erdafitinib in combination with enfortumab vedotin in treating patients with bladder cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and possesses genetic alterations in FGFR2/3 genes. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage IV Urethral Cancer AJCC v8, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8
Register for Updates
Cochlear Implantation in Children With Asymmetric Hearing Loss or Single-Sided Deafness Clinical Trial
NCT04793412
Recruiting
This is a two-phase study that compares performance growth pre-implant with current hearing aid (HA) technology versus post-implant with a cochlear implant (CI) in children with either asymmetric hearing loss (AHL) or single-sided deafness (SSD). Post-implant performance with a CI alone is expected to outperform pre-implant performance with a HA. The study also evaluates the effectiveness of bimodal hearing defined as a CI in the poor ear and a HA in the better ear for AHL or a CI in the poor ea... Read More
Gender:
ALL
Ages:
Between 4 years and 14 years
Trial Updated:
03/26/2025
Locations: Children's Hospital of Philadelphia - Buerger Center, Philadelphia, Pennsylvania
Conditions: Asymmetric Hearing Loss, Single-sided Deafness, Unilateral Deafness
Register for Updates
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628
Recruiting
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Register for Updates
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883
Recruiting
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/26/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Register for Updates
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
NCT04159103
Recruiting
This First-in-Human (FIH) Phase 1/2 study is designed to characterize the safety, tolerability, and pharmacological activity (as assessed by biomarker measurements) and to determine the optimal dose of mRNA-3927 in participants with genetically confirmed propionic acidemia (PA). After establishing a dose with acceptable safety and pharmacodynamic (PD) response in a Dose Optimization Group (Part 1) in participants ≥1 year of age, additional participants will be enrolled into the study in a Dose E... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania
Conditions: Propionic Acidemia
Register for Updates
Antidepressant Adherence for Depressed Adults in Primary Care
NCT06496646
Recruiting
The goal of this randomized controlled trial study is to compare different adherence support strategies for primary care patients with depression who have been newly prescribed antidepressant medications. We will examine whether personalized daily text messages with and without financial incentives improves anti-depressant adherence and depression symptoms as compared to treatment as usual (no messages or incentives for taking medications). We will measure adherence with a wireless pill bottle... Read More
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
03/25/2025
Locations: University of Pennsylvania Health System, Philadelphia, Pennsylvania
Conditions: Depression
Register for Updates
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
NCT06420089
Recruiting
This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: University of Pennsylvania - Abramson Caner Center, Philadelphia, Pennsylvania
Conditions: T Cell Non-Hodgkin Lymphoma
Register for Updates
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
NCT06347016
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: AMS Cardiology, Horsham, Pennsylvania
Conditions: Severe Hypertriglyceridemia
Register for Updates